

13-00000

AI  
emit

Claim 3. (Amended) The method of [Use according to] claim 1 [or 2], characterized in that the disturbance or illness of the inner ear is associated with at least one of the symptoms vertigo, impairment of hearing or tinnitus.

Claim 4. (Amended) The method of [Use according to] claim 3, characterized in that the impairment of hearing is a deep sound hearing impairment.

Claim 5. (Amended) The method of claim 1 [Use according to one of the preceding claims], characterized in that the disturbance or illness of the inner ear is linked with a hydrops, particularly an endolymphatic hydrops.

AI Unit

~~SECRET~~ - 070300

Claim 8. (Amended) The method of [Use according to] claim 7, characterized in that the peptide compound is a linear peptide, particularly propionyl-D-Tyr(Et)-Phe-Val-Asn-Abu-Pro-Arg-Arg-NH<sub>2</sub>.

Claim 9. (Amended) The method of claim 1 [Use according to one of the claims 1 to 6], characterized in that the receptor antagonist is a non-peptidic, preferably non-peptidic, organic substance.

Claim 10. (Amended) The method of [Use according to] claim 9, characterized in that the organic substance is a benzazepin derivative.

Claim 11. (Amended) The method of [Use according to] claim 10, characterized in that the benzazepin derivative is 5-dimethylamino-1-{4-(2-methyl-benzoylamino)-benzoyl}-2,3,4,5-tetrahydro-1H-benzazepin.

Claim 12. (Amended) The method of [Use according to] claim 9, characterized in that the organic substance is an indole derivative.

Claim 13. (Amended) The method of [Use according to] claim 12, characterized in that the indole derivative is 1-[4-(N-tert.-butyl carbamoyl)-2-methoxybenzene sulphonyl]-5-ethoxy-3-spiro-[4-(2-morpholinoethoxy)-cyclohexane]-indol-2-one fumarate.

Claim 14. (Amended) The method of claim 1 [Use according to one of the preceding claims], characterized in that the receptor antagonist can be administered orally and/or intravenously, particularly orally.

Claim 15. (Amended) The method of claim 1 [Use according to one of the preceding claims], characterized in that the receptor antagonist is used in a quantity of 0.1 to 50 mg/kg of body weight and per day.

Claim 16. (Amended) The method of claim 1 [Use according to one of the preceding claims], characterized in that the receptor antagonist is contained in a formulation or medicament intended for administration in a quantity of 1 to 75 wt.%, preferably 5 to 50 wt.%, preferably 5 to 25 wt.%.

AI  
Cm  
00530693-070300

AI  
Cm

17. Process for the treatment of disturbances or illnesses of the inner ear, characterized in that at least one vasopressin receptor antagonist or mixtures of such antagonists is administered in a suitable, compatible quantity.

---

Claim 18. (Amended) The process [Process] according to claim

A2 17, characterized by [at least one of the features of claims 2 to 16] the features of claim 2.

---

19. Pharmaceutical composition or medicament for the treatment of disturbances or illnesses of the inner ear, characterized in that at least one vasopressin receptor antagonist or mixtures of such antagonists is contained.

---

Claim 20. (Amended) The composition [Composition] or

A3 medicament according to claim 19, characterized by [at least one of the features of claims 7 to 16] the features of claim 7.

---